Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health
Ning H, Sun Z, Liu Y, Liu L, Hao L, Ye Y, et al
9 Amino Acids 848.82 Da (WAGGDASGE) Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
The brand's own disclaimer states the product isn't intended to diagnose, treat, cure, or prevent any disease, and this article does not independently classify the product beyond what the brand discloses
: